Myeloproliferative neoplasm: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 16: Line 16:
{{Myeloproliferative disease}}
{{Myeloproliferative disease}}
{{CMG}}
{{CMG}}
==Overview==
==[[Myeloproliferative disease overview|Overview]]==


The '''myeloproliferative diseases''' ("MPD"s) are a group of diseases of the [[bone marrow]] in which excess cells are produced. They are related to, and may evolve into, [[myelodysplastic syndrome]] and [[acute myeloid leukemia]], although the myeloproliferative diseases on the whole have a much better prognosis than these conditions.
==[[Myeloproliferative disease historical perspective|Historical Perspective]]==
==Historical perspective==
The concept of myeloproliferative disease was first proposed in 1951 by the eminent hematologist [[William Dameshek]].<ref>{{cite journal | author = Dameshek W | title = Some speculations on the myeloproliferative syndromes. | journal = Blood | volume = 6 | issue = 4 | pages = 372-5 | year = 1951 | id = PMID 14820991}}</ref>


==Classification==
==[[Myeloproliferative disease classification|Classification]]==
Although not a [[cancer|malignant neoplasm]], MPDs are classified within the [[Hematological malignancy|hematological neoplasms]].


There are four main myeloproliferative diseases, which can be further categorized by the presence of the [[Philadelphia chromosome]]:
==[[Myeloproliferative disease pathophysiology|Pathophysiology]]==


{| class="wikitable"
==[[Myeloproliferative disease causes|Causes]]==
|-
! Philadelphia Chromosome "positive"
! Philadelphia Chromosome "negative"
|-
|
* [[Chronic myelogenous leukemia]] (CML)
|  
* [[Polycythemia vera]] (PV)
* [[Essential thrombocytosis]] (ET)
* [[Myelofibrosis]] (MF)
|-
|}


==Pathophysiology==
==[[Myeloproliferative disease differential diagnosis|Differentiating Myeloproliferative disease from other Diseases]]==


In 2005, the discovery of the JAK2 V617F mutation provided some evidence to suggest a common pathogenesis for the Philadelphia Chromosome negative MPDs.<ref>{{cite journal | author = Baxter EJ, Scott LM, Campbell PJ, et al. | title = Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. | journal = Lancet | volume = 365 | pages = 1054-1061 | year = 2005 | id = PMID 15781101}}</ref><ref>{{cite journal | author = James C, Ugo V, Le Couedic JP, et al. | title = A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. | journal = Nature | volume = 434 | issue = 7037 | pages = 1144–1148 | year = 2005 | id = PMID 15793561}}</ref><ref>{{cite journal | author = Levine RL, Wadleigh M, Cools J, et al. | title = Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | journal = Cancer Cell | volume = 7 | issue = 4 | pages = 387–397  | year = 2005 | id = PMID 15837627}}</ref><ref>{{cite journal | author = Kralovics R, Passamonti F, Buser AS, et al. | title = A gain-of-function mutation of JAK2 in myeloproliferative disorders | journal = N Engl J Med | volume = 352 | issue = 17 | pages = 1779–1790 | year = 2005 | id = PMID 15858187}}</ref><ref>{{cite journal | author = Campbell PJ, Scott LM, Buck G, et al. | title = Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study | journal = Lancet | volume = 366 | issue = 9501 | pages = 1945–1953 | year = 2005 | id = PMID 16325696}}</ref>
==[[Myeloproliferative disease epidemiology and demographics|Epidemiology and Demographics]]==


==Causes==
==[[Myeloproliferative disease risk factors|Risk Factors]]==
All MPDs arise from precursors of the "[[myeloid]]" lineage in the bone marrow.


==Differentiating Myeloproliferative disease from other Diseases==
The lymphoid lineage may produce similar diseases, the [[lymphoproliferative disorder]]s ([[acute lymphoblastic leukemia]], [[lymphoma]]s, [[chronic lymphocytic leukemia]] and [[multiple myeloma]]).


== Diagnosis==
Depending on the nature of the myeloproliferative disorder, diagnostic tests may include red cell mass determination (for polycythaemia), bone marrow aspirate and trephine biopsy, arterial oxygen saturation and carboxyhaemoglobin level, neutrophil alkaline phosphatase level, vitamin B12 (or B12 binding capacity) and serum urate.<ref>{{cite book |author=Levene, Malcolm I.; Lewis, S. M.; Bain, Barbara J.; Imelda Bates |title=Dacie & Lewis Practical Haematology |publisher=W B Saunders |location=London |year= |pages= |isbn=0-443-06377-X |pages=586}}</ref>


==[[Myeloproliferative disease screening|Screening]]==
==[[Myeloproliferative disease natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
==Diagnosis==
[[Myeloproliferative disease history and symptoms| History and Symptoms]] | [[Myeloproliferative disease physical examination | Physical Examination]] |[[Myeloproliferative disease laboratory findings|Laboratory Findings]] | [[Myeloproliferative disease chest x ray|Chest X Ray]] |  [[Myeloproliferative disease CT|CT]] | [[Myeloproliferative disease MRI|MRI]] | [[Myeloproliferative diseaseultrasound|Ultrasound]] | [[Myeloproliferative disease other imaging findings|Other Imaging Findings]] | [[Myeloproliferative disease other diagnostic studies|Other Diagnostic Studies]]
==Treatment==
[[Myeloproliferative disease medical therapy|Medical Therapy]] | [[Myeloproliferative disease surgery|Surgery]] |[[Myeloproliferative disease primary prevention|Primary Prevention]] | [[Myeloproliferative disease secondary prevention|Secondary Prevention]] | [[Myeloproliferative disease cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Myeloproliferative disease future or investigational therapies|Future or Investigational Therapies]]
==Case Studies==
[[Myeloproliferative disease case study one|Case#1]]
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
== External links ==
* [http://www.mpdinfo.org/ Myeloproliferative Disorders Website of The CMPD Education Foundation]
*[http://www.mpdfoundation.org MPD Foundation and Research Alliance - Register for a free newsletter]


{{Hematology}}
{{Hematology}}
Line 65: Line 54:


[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Disease]]


[[ar:مرض التكاثر النقوي]]
[[ar:مرض التكاثر النقوي]]
Line 71: Line 62:
[[fr:Syndrome myéloprolifératif]]
[[fr:Syndrome myéloprolifératif]]
[[pl:Zespoły mieloproliferacyjne]]
[[pl:Zespoły mieloproliferacyjne]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Revision as of 15:15, 21 September 2012

Template:DiseaseDisorder infobox

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm

on Myeloproliferative neoplasm

Myeloproliferative neoplasm in the news

Blogs on Myeloproliferative neoplasm

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myeloproliferative disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination |Laboratory Findings | Chest X Ray | CT | MRI | Ultrasound | Other Imaging Findings | Other Diagnostic Studies

Treatment

Medical Therapy | Surgery |Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies


Case Studies

Case#1

References

Template:Hematology


ar:مرض التكاثر النقوي de:Myeloproliferative Erkrankung


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Myeloproliferative_neoplasm&oldid=748798"